{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:57:15Z","timestamp":1772384235291,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771363"],"award-info":[{"award-number":["81771363"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jocn.2021.11.020","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:07:32Z","timestamp":1639051652000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis"],"prefix":"10.1016","volume":"95","author":[{"given":"Li-Min","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jocn.2021.11.020_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.jocn.2021.11.020_b0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2021.11.020_b0015","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jocn.2021.11.020_b0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2021.11.020_b0025","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jocn.2021.11.020_b0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.jocn.2021.11.020_b0035","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jocn.2021.11.020_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.593431","article-title":"Immunoregulatory cells in myasthenia gravis","volume":"11","author":"Wu","year":"2020","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2021.11.020_b0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Egwuagu, Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"issue":"7492","key":"10.1016\/j.jocn.2021.11.020_b0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jocn.2021.11.020_b0055","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/eji.201445217","article-title":"Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members","volume":"45","author":"Dixon","year":"2015","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.jocn.2021.11.020_b0060","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur J Immunol"},{"issue":"7169","key":"10.1016\/j.jocn.2021.11.020_b0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2021.11.020_b0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2016.03.004","article-title":"Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders","volume":"293","author":"Zhang","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.jocn.2021.11.020_b0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MAJ.0000000000000215","article-title":"Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus","volume":"348","author":"Ouyang","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jocn.2021.11.020_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jocn.2021.11.020_b0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jocn.2021.11.020_b0090","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nri.2016.75","article-title":"Immunity by equilibrium","volume":"16","author":"Eberl","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jocn.2021.11.020_b0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.0105-2896.2006.00415.x","article-title":"The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells","volume":"212","author":"Shevach","year":"2006","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.jocn.2021.11.020_b0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jocn.2021.11.020_b0105","first-page":"131","article-title":"IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells","volume":"24","author":"Castellani","year":"2010","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jocn.2021.11.020_b0110","first-page":"623","article-title":"Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis","volume":"8","author":"Kong","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jocn.2021.11.020_b0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cyto.2016.12.011","article-title":"Increased IL-35 producing Tregs and CD19(+)IL-35(+) cells are associated with disease progression in leprosy patients","volume":"91","author":"Tarique","year":"2017","journal-title":"Cytokine"},{"issue":"1pt2","key":"10.1016\/j.jocn.2021.11.020_b0120","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.jocn.2021.11.020_b0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2021.11.020_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01258","article-title":"IL-12p35 Inhibits neuroinflammation and ameliorates autoimmune encephalomyelitis","volume":"8","author":"Choi","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.020_b0135","doi-asserted-by":"crossref","first-page":"e33628","DOI":"10.1371\/journal.pone.0033628","article-title":"IL-35 is a novel responsive anti-inflammatory cytokine\u2013a new system of categorizing anti-inflammatory cytokines","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2021.11.020_b0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-alpha","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2021.11.020_b0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jocn.2021.11.020_b0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"issue":"1-2","key":"10.1016\/j.jocn.2021.11.020_b0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2010.10.020","article-title":"Clinical and biological heterogeneity of autoimmune myasthenia gravis","volume":"231","author":"Pal","year":"2011","journal-title":"J Neuroimmunol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821005671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821005671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:28:37Z","timestamp":1760822917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821005671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"alternative-id":["S0967586821005671"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.11.020","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}